WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
»õ·Î¿î COVID-19 »ç·Ê¿Í »ç¸Á·üÀº Áö³ ÁÖ¿¡ °¢°¢ 6%¿Í 4??% ¾¿ °è¼Ó Áõ°¡Çß´Ù (±×¸² 1, Ç¥ 1). ¹ÌÁÖ Áö¿ªÀÌ ´Ù½Ã °¡Àå Å« ºñÀ²À» Â÷ÁöÇÏ¿© 230 ¸¸ °Ç (Àü ¼¼°è ´©ÀûÀÇ Àý¹Ý)ÀÌ ³Ñ´Â »õ·Î¿î »ç·Ê¸¦ º¸°íÇßÀ¸¸ç, À¯·´Áö¿ªÀº Áö³ ÁÖ¿¡ °¡Àå ¸¹Àº ½Å±Ô »ç¸ÁÀÚ (36,286, 46 %)¸¦ º¸°íÇß´Ù.
¾ÆÇÁ¸®Ä« Áö¿ªÀº ÀüÁÖ¿¡ ºñÇØ ½Å±Ô»ç·Ê(27%)¿Í »ç¸Á(34%)ÀÌ »ó´ëÀûÀ¸·Î °¡Àå ¸¹ÀÌ Áõ°¡Çß´Ù. Áõ°¡ Ãß¼¼´Â ¼ÅÂÆò¾ç Áö¿ª¿¡¼µµ °üÂûµÇ¾úÀ¸¸ç, µ¿³²¾Æ½Ã¾Æ¿Í ÁöÁßÇØ µ¿ºÎ Áö¿ªÀº »ç·Ê¿Í »ç¸ÁÀÌ ¸ðµÎ °¨¼ÒÇÑ °ÍÀ¸·Î º¸°í µÈ À¯ÀÏÇÑ µÎ °÷ÀÌ´Ù.
2020³â 12¿ù 14ÀÏ ¿µ±¹ ¹× ºÏ ¾ÆÀÏ·£µå ´ç±¹Àº »õ·Î¿î º¯Á¾ SARS-CoV-2¸¦ WHO¿¡ º¸°íÇß´Ù. ÀÌ´Â ÇöÀç ¹ÙÀÌ·¯½º °Ô³ð ½ÃÄö½Ì(viral genomic sequencing)À¸·Î È®ÀεǾúÀ¸¸ç, SARS-CoV-2 º¯Á¾(SARS-CoV-2 Variant )À¸·Î 2020³â, 12°³¿ù, º¯Á¾01 (SARS-CoV-2 VUI 202012/01) À¸·Î ºÐ·ùµÇ¾î, ÇöÀç Á¶»ç Áß¿¡ ÀÖ´Ù. Ãʱ⠺м®°á°ú´Â ÀÌ »õ·Î¿î ¹ÙÀÌ·¯½º °Ô³ð ½ÃÄö½Ì º¯Á¾(SARS-CoV-2 VUI 202012/01)ÀÌ »ç¶÷°£ ÀüÆÄ°¡ ´õ¿í ½±°Ô È®»êµÉ ¼ö ÀÖÀ½À» ³ªÅ¸³»°í ÀÖ´Ù. ÀÌ ¹ÙÀÌ·¯½º º¯Á¾ÀÇ °¨¿°ÀÇ ½É°¢¼º, Ç×ü ¹ÝÀÀ ¶Ç´Â ¹é½Å È¿´ÉÀÇ º¯È¿¡ ´ëÇÑ °ü·Ã¼ºÀ» È®ÀÎÇϱâÀ§ÇÑ Á¶»ç°¡ ÇöÀç ÁøÇà ÁßÀÌ´Ù.
COVID-19 °¨¿°ÀÌ È®»êµÇ±â ½ÃÀÛÇÑ ÀÌÈÄ ÇöÀç(WHO º¸°í, 12¿ù 20ÀÏÀÚ ±âÁØ)±îÁö 7,500¸¸°Ç ÀÌ»óÀÇ »ç·Ê¿Í 160¸¸¸í ÀÌ»óÀÇ »ç¸ÁÀÚ°¡ ¹ß»ýÇß´Ù.
±×¸² 1. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO Áö¿ªº° È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 2. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¾Æ¸Þ¸®Ä«Áö¿ª, È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 3. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¾ÆÇÁ¸®Ä«Áö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 4. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO µ¿ºÎÁöÁßÇØÁö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 5. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO À¯·´Áö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 5. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO µ¿³²¾Æ½Ã¾ÆÁö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 20 December, 2020)
±×¸² 7.COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¼ÅÂÆò¾çÁö¿ª, È®ÁøÀÚ »ç¸ÁÀÚ, as 20 December, 2020)
ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²
COVID-19 ±¹¿Ü¹ß»ýÇöȲÀº Áö¿ªº°·Î ¾Æ½Ã¾ÆÁö¿ª 29°³±¹, Áßµ¿Áö¿ª 18°³±¹, ¾Æ¸Þ¸®Ä«Áö¿ª 35°³±¹, À¯·´Áö¿ª 49°³±¹, ¿À¼¼¾Æ´Ï¾ÆÁö¿ª 4°³±¹, ¾ÆÇÁ¸®Ä«Áö¿ª 49°³±¹, ±×¿Ü ±âŸÁö¿ª Æ÷ÇÔÇÏ¿©, Àü¼¼°èÀûÀ¸·Î COVID-19 È®ÁøÀÚ´Â 78,011,432¸í(½Å±Ô4,612,790¸í), »ç¸ÁÀÚ 1,717,055¸í(½Å±Ô79,001¸í)À¸·Î º¸°íµÇ¾ú´Ù(2020³â 12¿ù 23ÀÏÀÚ ±âÁØ, Johns Hopkins Uni. COVID-19 Dashboard CSSE).
Àü ¼¼°è¿¡¼ °¡Àå ¸¹Àº »ç·Ê¸¦º¸°í ÇÑ ³ª¶ó´Â Áö³ ÁÖ ±âÁØÀ¸·Î ¹Ì±¹ÀÌ 1À§¸¦ Â÷ÁöÇÏ¿´°í, 160¸¸°ÇÀÌ»óÀ¸·Î ÇÑÁÖ Àüº¸´Ù 14% Áõ°¡ ÇÏ¿´´Ù. ±× µÚ¸¦ ÀÌ¾î ºê¶óÁú(326,751 °Ç, ÀüÁÖ ´ëºñ 8% Áõ°¡), ÅÍÅ°(½Å±Ô 194476°Ç, ÀüÁÖ ´ëºñ 11 %°¨¼Ò), ·¯½Ã¾Æ ¿¬¹æ(½Å±Ô 194,449°Ç, ÀüÁÖ ´ëºñ 1 % ¹Ì¸¸) ¹× Àεµ(174,194 °ÇÀÇ ½Å±Ô »ç·Ê, ÀüÁÖ ´ëºñ 18 % °¨¼Ò)·Î ³ªÅ¸³µ´Ù.
Globally ÃÑ È®ÁøÀÚ 78,011,432¸í(½Å±Ô4,612,790¸í), »ç¸ÁÀÚ 1,717,055¸í(½Å±Ô79,001¸í) (2020³â 12¿ù 23ÀÏ ±âÁØ, COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
Àü ¼¼°è¿¡¼ °¡Àå ¸¹Àº »ç·Ê¸¦º¸°í ÇÑ ³ª¶ó´Â Áö³ ÁÖ ±âÁØÀ¸·Î ¹Ì±¹ÀÌ 1À§¸¦ Â÷ÁöÇÏ¿´°í, 160¸¸°ÇÀÌ»óÀ¸·Î ÇÑÁÖ Àüº¸´Ù 14% Áõ°¡ ÇÏ¿´´Ù. ±× µÚ¸¦ ÀÌ¾î ºê¶óÁú(326,751 °Ç, ÀüÁÖ ´ëºñ 8% Áõ°¡), ÅÍÅ°(½Å±Ô 194476°Ç, ÀüÁÖ ´ëºñ 11 %°¨¼Ò), ·¯½Ã¾Æ ¿¬¹æ(½Å±Ô 194,449°Ç, ÀüÁÖ ´ëºñ 1 % ¹Ì¸¸) ¹× Àεµ(174,194 °ÇÀÇ ½Å±Ô »ç·Ê, ÀüÁÖ ´ëºñ 18 % °¨¼Ò)·Î ³ªÅ¸³µ´Ù.
Ç¥1) ¼¼°èº¸°Ç±â±¸(WHO) Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Áö¿ªº° 12¿ù 20ÀÏÀÚ)
±¸ºÐ
|
¾ÆÇÁ¸®Ä«
|
¾Æ¸Þ¸®Ä«
|
µ¿ºÎÁöÁßÇØ
|
À¯·´
|
µ¿³²¾Æ½Ã¾Æ
|
¼ÅÂÆò¾ç
|
È®ÁøÀÚ(¸í)
|
1 716 697 (2%)
|
32 437 597 (43%)
|
4 665 285 (6%)
|
23 691 857 (32%)
|
11 610 444 (15%)
|
1 006 682 (1%)
|
»ç¸ÁÀÚ(¸í)
|
37 741 (2%)
|
809 105 (48%)
|
115 495 (7%)
|
522 719 (31%)
|
176 826 (11%)
|
18 895 (1%)
|
Ä¡¸í·ü(CFR)
|
2.20%
|
2.49%
|
2.48%
|
2.21%
|
1.52%
|
1.88%
|
±×¸² 8) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â12¿ù20ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Global Summary Report (as 20 December)
Ç¥ 2) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â12¿ù 20ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Global Summary Report (as 20 December)
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
COVID-19 ¼¼°¡Áö Áø´Ü°Ë»ç ºñ±³ : ºñÀεεµ¸» PCR, Ÿ¾× PCR, ½Å¼ÓÇ׿ø°Ë»ç - Three COVID-19 Diagnostic Tests in Korea -
"ºñÀεεµ¸» PCR→Ÿ¾× PCR→½Å¼ÓÇ׿ø°Ë»ç ¼ø ±ÇÀå…°Ë»ç°á°ú Á¤È®µµ Â÷ÀÌ"
¿ì¸®³ª¶ó¿¡¼ ÇöÀç ½ÃÇàµÇ°í ÀÖ´Â ¼¼°¡Áö Äڷγª19 °Ë»çÁø´Ü¹ý¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù. Áúº´°ü¸®Ã» Á߾ӹ濪´ëÃ¥º»ºÎ´Â Äڷγª19 Á¤·Êºê¸®Çο¡¼ ¼¼ °¡Áö Äڷγª19 °Ë»ç¹ý¿¡ ´ëÇØ ¼³¸íÇÏ¸é¼ ¹Î°¨µµ(Sensitivity)¿Í ƯÀ̵µ(specificity)¸¦ °ø°³Çß´Ù. Ç¥ÁØ°Ë»ç¹ýÀÎ ºñÀεεµ¸» PCR(½Ç½Ã°£ ¿ªÀü»ç ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ, rRT-PCR, qRT-PCR)Àº ¹Î°¨µµ 98% ÀÌ»ó, ƯÀ̵µ 100%À̸ç Ÿ¾× PCRÀº ¹Î°¨µµ 92%, ƯÀ̵µ 100%´Ù. ¹Ý¸é, ½Å¼ÓÇ׿ø°Ë»ç¹ýÀº ¹Î°¨µµ 90%, ƯÀ̵µ 96%·Î ¼¼ °¡Áö °Ë»ç¹ý Áß °¡Àå ³·´Ù[»ó¼¼º¸±â]
³ëÈÀÇ °üÁ¡¿¡¼ COVID-19 ÀÓ»óÀû ¾ç»ó - COVID-19 ³ëÀΠȯÀÚÀÇ ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·Â
Understanding the Clinical Features of Coronavirus Disease 2019 From the Perspective of Aging: A Systematic Review and Meta-Analysis
-High Inflammatory State and Low Immune Defense of the Aging Patients With COVID-19-
ÀÓ»óÁú¹® :
³ëÀε鿡°Ô Äڷγª19 °¨¿°ÀÌ ´õ¿í À§Çè°ÍÀº ÀþÀº Ãþ¿¡ ºñÇÏ¿© ³·Àº ¸é¿ª¹æ¾î ´É·ÂÀ̳ª ³ôÀº ¿°Áõ»óÅÂ¿Í °ü·ÃÀÌ ÀÖ½À´Ï±î?
¿¬±¸´äº¯ :
³ëÀÎÃþ ȯÀÚÀÇ Ç÷¾×°Ë»ç°á°ú ÀþÀº Ãþ¿¡ ºñÇÏ¿© ¹éÇ÷±¸ÀÇ ³ôÀº °¡º¯¼ºÀ» ³ªÅ¸³»¾ú´Ù. COVID-19 ³ëÀÎȯÀÚÀÇ ½ÇÇè½Ç °á°ú ³ôÀº ¿°Áõ»óÅ ¹× ³·Àº ¸é¿ª¹æ¾î´É·ÂÀ¸·Î COVID-19 ³ëÀÎ Àα¸¿¡¼ COVID-19·Î ÀÎÇÑ Ãë¾à¼º°ú ºÒ¾ÈÁ¤ÇÑ »óŸ¦ ³ªÅ¸³»¾ú´Ù. Ç÷¾×°Ë»ç °á°ú C- ¹ÝÀÀ¼º ´Ü¹éÁú, ÇÁ·Î Ä®½ÃÅä´Ñ ¹× ÀÎÅÍ·çŲ -6 (C-reactive protein, procalcitonin, and interleukin-6) Åë°è ºÐ¼®À» ¼öÇàÇÏ¿© ³ëÀΠȯÀÚÀÇ ¿°Áõ ¹× ¸é¿ª ¹ÝÀÀÀ» Ãß·ÐÇÏ°í Ç÷¼ÒÆÇ°ú D-dimer¸¦ °è»êÇÏ¿© ³ëÀΠȯÀÚÀÇ ÀÀ°í±â´ÉÀ» È®ÀÎÇÏ¿´´Ù[»ó¼¼º¸±â]
[NEJM] ÈÀÌÀÚ & ¹ÙÀÌ¿À¿£Å×Å© COVID-19 ¹é½Å(Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine) ÀÓ»ó°á°ú ¹× ºÎÀÛ¿ë ¹ßÇ¥
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
¹Ì±¹ Á¦¾àȸ»ç ÈÀÌÀÚ¿Í µ¶ÀÏ »ý¸í°øÇбâ¾÷ ¹ÙÀÌ¿À¿£Å×Å©(BioNTech SE)´Â mRNA ±â¹Ý Äڷγª19 ¹é½Å Èĺ¸¹°Áú ‘BNT162b2’ÀÇ ÀÓ»ó 3»ó ½ÃÇè¿¡¼ µµÃâµÈ ¾ÈÀü¼º ¹× È¿´É¼º °á°ú¿¡ ´ëÇØ ÀÇÇÐ ÇмúÁö ‘´º À×±Û·£µå Àú³Î ¿Àºê ¸Þµð½¼’(NEJM)¿¡ °ÔÀçµÆ´Ù°í 10ÀÏÀÚ·Î ¹ßÇ¥Çß´Ù[»ó¼¼º¸±â].
COVID-19 ȯÀÚÀÇ Ä¡¸íÀ², ÀÓ»óƯ¼º, Åð¿øÀ²
COVID?19 patients' clinical characteristics, discharge rate, and fatality rate of meta?analysis
ÀÌ ¿¬±¸´Â COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î COVID-10ȯÀÚÀÇ Åð¿ø·ü ¹× »ç¸Á·üÀ» ºÐ¼®ÇϱâÀ§ÇØ 2019 ³â 12 ¿ùºÎÅÍ 2020 ³â 2 ¿ù±îÁö COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅÍ´Â 4 °³ÀÇ µ¥ÀÌÅͺ£À̽º¿¡¼ °Ë»öÇÏ¿´´Ù. COVID-19 ȯÀÚÀÇ ÀÓ»ó Áõ»ó°ú °Ë»ç½Ç °á°ú¸¦ Åë°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ´ÜÀÏ ±º ¸ÞŸ ºÐ¼®À¸·Î Åð¿øÀ² °ú »ç¸Á·üÀ» ¼³¸íÇß´Ù. 10°³ÀÇ ¹®Çå¿¡¼ 1994 ³â ȯÀÚÀÇ ÀÌ¿ë °¡´ÉÇÑ µ¥ÀÌÅÍ°¡ ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. [»ó¼¼º¸±â]
Source: Johns Hopkins University CSSE COVID 19 Data-Last Updated 8 December, 21:06 (London time)
[JAMA] COVID-19 °¨¿°µÈ »ê¸ð¿¡¼ ÅÂ¾î³ ½Å»ý¾Æ´Â COVID-19 Ç×üº¸À¯ (Antibodies in Infants Born to Mothers With COVID-19 Pneumonia)
JAMA¿¡ ¹ßÇ¥µÈ À̹ø ¿¬±¸´Â COVID-19°¡ È®Áø µÈ 6 ¸íÀÇ ÀÓ»êºÎ¿Í ½Å»ý¾Æ¿¡°Ô »õ·Î¿î Ç÷ûÇÐÀû ±âÁØÀ¸·Î ½Å»ý¾Æ °¨¿°¿¡ ´ëÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¶»ç ±âÁØÀ» Àû¿ëÇؼ COVID-19¿¡ °¨¿°µÈ ¸ð¼º¿¡°Ô¼ ÅÂ¾î³ ½Å»ý¾ÆÀÇ COVID-19 Ç×ü º¸À¯¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ¿´´Ù. [»ó¼¼º¸±â]
COVID-19 Vaccines ºñ±³: ÈÀÌÀÚ(Pfizer & BioNTech), ¸ð´õ³ª(Moderna) & ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)
¹Ì±¹ ÈÀÌÀÚ¿Í µ¶ÀÎ ¹ÙÀÌ¿À¿£Å×Å©(Pfizer & BioNTech) °³¹ßÇÑ COVID-19 ¹é½Å°ú ¹Ì±¹ ¸ð´õ³ª(Moderna) Á¦¾àȸ»çÀÇ ¹é½Å °³¹ß ¹ßÇ¥¿¡ À̾î, ¿µ±¹°è ´Ù±¹Àû Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)´Â 23ÀÏ Èıâ ÀÓ»ó½ÃÇè¿¡¼ 90% È¿°ú°¡ ÀÖ´Â °·ÂÇÑ COVID-19 ¹é½ÅÀÇ ÀÓ»ó½ÃÇè °á°ú¸¦ ÀÕ´Þ¾Æ ¹ßÇ¥Çß´Ù. ÀÌÁ¦ Àü¼¼°è´Â Äڷγª19 °¨¿°À» µåµð¾î ³¡³¾ ¹é½ÅÀÌ °³¹ßµÈ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 5) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â
Ç¥ 6) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø
References
Çѱ¹ : Á߾ӹ濪´ëÃ¥º»ºÎ Á¤·Êºê¸®ÇÎ º¸µµÀÚ·á
WHO: Weekly epidemic update-22- December 2020
Áß±¹ : ±¹°¡À§»ý°Ç°À§¿øȸ ȨÆäÀÌÁö
ÀÌÅ»¸®¾Æ : º¸°ÇºÎ ȨÆäÀÌÁö
ÀϺ» : ÈÄ»ý³ëµ¿¼º º¸µµÀÚ·á
¿µ±¹ : Á¤ºÎ»çÀÌÆ®
À̶õ · ¹Ì±¹ : Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE